Clinical trial
Synthetic Human Secretin in Children With Autism
NCT00036244 · Repligen Corporation, Industry · Completed
Key facts
| NCT number | NCT00036244 |
|---|---|
| Title | Synthetic Human Secretin in Children With Autism |
| Official title | A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Assess the Efficacy, Safety and Tolerability of RG1068 (Synthetic Human Secretin) in Children With Autism |
| Lead sponsor | Repligen Corporation, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Autism |
| Intervention type | Drug |
| Interventions | RG1068 (Synthetic Human Secretin) |
| Start date | Apr 1, 2002 |
| Completion | Jan 1, 2004 |
| First posted | May 9, 2002 |
| Last update posted | Aug 5, 2005 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: